March 14, 2017
Allergan plc and Editas Medicine Inc., a genome editing company, announced that Allergan’s subsidiary, Allergan Pharmaceuticals International Limited, and Editas Medicine have entered into a strategic research and development agreement. The agreement states that Allergan will have full access and licensing options for up to five of Editas's genome-editing ocular programs. The deal covers programs that target serious diseases based on Editas's CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a programmable tool that targets specific areas of genetic code and edits DNA at specific locations in the human genome. This allows researchers to modify genes and potentially create medicines with sustainable treatment effects.
Also included in the agreement is Editas's lead program, which is currently preclinical, for the potential treatment of LCA10 (Leber congenital amaurosis)-a rare, inherited retinal degenerative disease that appears in childhood and leads to blindness.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Expanding Immune Response Testing to Support Vaccine Development
April 22nd 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and CAR T cell therapy.